---
name: Semaglutide
slug: semaglutide
aliases:
  - Ozempic
  - Wegovy
  - Rybelsus
classes:
  - glp-1-receptor-agonists
targets:
  - glp-1r
evidence_floor: human_rct
index: 10
---

import ClaimCallout from "../../components/ClaimCallout.astro";

## Overview
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that has been extensively studied in human randomized controlled trials for metabolic indications, including type 2 diabetes and obesity.  

Its pharmacological profile is characterized by high receptor affinity, prolonged half-life, and once-weekly administration in injectable formulations, with additional oral formulations evaluated using absorption enhancers.

---

## Mechanism of action
<ClaimCallout
  claim="GLP-1 receptor agonism is associated with appetite regulation, delayed gastric emptying, and improved glycemic control in humans."
  evidence="human_rct"
  confidence="high"
/>

Semaglutide activates the GLP-1 receptor, a G-protein-coupled receptor expressed in pancreatic, gastrointestinal, and central nervous system tissues.  
Reported downstream effects in clinical studies include:
- Glucose-dependent stimulation of insulin secretion  
- Suppression of glucagon release  
- Central appetite and satiety signaling  
- Slowing of gastric emptying, particularly during early treatment phases  

These mechanisms collectively contribute to observed metabolic outcomes in trial settings.

---

## Evidence summary
A substantial body of **large-scale human randomized controlled trials** supports the metabolic effects of semaglutide across multiple indications.

Across study programs, semaglutide has been associated with:
- Statistically significant reductions in HbA1c in type 2 diabetes populations  
- Clinically meaningful reductions in body weight in obesity-focused trials  
- Improvements in several cardiometabolic risk markers  

The evidence base includes multi-year studies with active comparators and placebo controls, forming one of the strongest clinical datasets among GLP-1 receptor agonists.

---

## Safety & known risks
Across clinical trials, semaglutide demonstrated a **predictable and largely class-consistent safety profile**.

Most frequently reported adverse events include:
- Nausea  
- Vomiting  
- Diarrhea  
- Constipation  

These effects were typically:
- Dose-dependent  
- Most prominent during initiation or dose escalation  
- Reported as mild to moderate in severity in the majority of participants  

Serious adverse events were uncommon in trial populations but continue to be monitored in long-term and post-marketing studies.

---

## ðŸ”¬ Clinical & observational context *(research-oriented)*

> **Important:** This section summarizes patterns reported in scientific literature and does not constitute medical advice.

### Reported dosing ranges (research context)
Across major human randomized controlled trials, semaglutide dosing, efficacy, and metabolic effects were indication-specific, protocol-defined, and evaluated over predefined study durations.
Type 2 diabetes (SUSTAIN program)
Injectable semaglutide was evaluated at 0.5 mg and 1.0 mg once weekly, following a 0.25 mg once-weekly initiation phase lasting approximately 4 weeks. Glycemic improvements were consistently observed after escalation to 0.5 mg, with additional dose-dependent effects at 1.0 mg.
Across SUSTAIN trials (typically 30â€“56 weeks, with longer follow-up in cardiovascular outcomes studies):
HbA1c reductions of approximately 1.0â€“1.8 percentage points were reported
Body weight reductions generally ranged from ~4% to 7%, depending on baseline characteristics and comparator
Waist circumference, fasting glucose, and insulin resistance markers showed favorable changes
Modest reductions in systolic blood pressure and improvements in lipid parameters (e.g. triglycerides, LDL-C) were observed
Cardiovascular outcomes trials (e.g. SUSTAIN-6, median follow-up >2 years) demonstrated a reduction in major adverse cardiovascular events, supporting broader cardiometabolic relevance beyond glycemic control.

Overweight and obesity (STEP program)
In obesity-focused trials, injectable semaglutide was studied at a target maintenance dose of 2.4 mg once weekly, reached via stepwise titration over ~16 weeks (0.25 â†’ 0.5 â†’ 1.0 â†’ 1.7 â†’ 2.4 mg).
Across STEP trials (typically 68 weeks total duration):
Mean body-weight reduction of approximately 14â€“16% from baseline was reported in semaglutide arms
A substantial proportion of participants achieved â‰¥10% and â‰¥15% weight loss
Waist circumference reductions were pronounced and dose-aligned
Improvements were observed in blood pressure, inflammatory markers, and lipid profiles
Glycemic markers improved even in participants without diabetes
Weight reduction was detectable during titration but was primarily assessed after sustained exposure at 2.4 mg, where outcomes plateaued and stabilized.

Oral semaglutide (PIONEER program)
Oral semaglutide was evaluated at 7 mg and 14 mg once daily, following an initial 3 mg daily starter phase. Trials generally lasted 26â€“52 weeks.
Reported findings include:
HbA1c reductions comparable to injectable lower-dose semaglutide at 14 mg daily
Modest weight loss, typically in the ~3â€“5% range
Improvements in fasting glucose, lipid markers, and select cardiometabolic parameters
The 3 mg dose was consistently described as non-therapeutic, with efficacy observed only after escalation.

---

### Titration patterns reported in trials
Most studies implemented **gradual dose escalation schedules**, typically over several weeks, with the explicit goal of improving gastrointestinal tolerability and reducing early discontinuation.

Rapid escalation was consistently associated with higher rates of gastrointestinal adverse events.

---

### Observed effects and adverse events
In addition to gastrointestinal symptoms, trials reported:
- Reduced appetite and spontaneous caloric intake  
- Early changes in gastric emptying dynamics  
- Modest heart-rate increases in some participants  

Neuropsychiatric and endocrine effects outside glucose regulation were not consistently observed and remain an area of ongoing investigation.

---

### Mitigation strategies discussed in clinical literature
Clinical publications frequently reference:
- Slower dose escalation  
- Temporary dose holds during intolerance  
- Dietary adjustments during initiation phases  

These approaches were studied as **trial-management strategies**, not individualized treatment recommendations.

---

### Studied or hypothesised interactions
In research settings, semaglutide has been evaluated in combination or comparison with:
- Other incretin-based therapies  
- Amylin analogues  
- Lifestyle interventions  

Combination pharmacotherapy remains investigational and indication-specific.

---

## Unknowns & research gaps
Despite extensive clinical evaluation, several areas remain under study:
- Long-term outcomes following treatment discontinuation  
- Durability of weight loss without continued therapy  
- Inter-individual variability in response  
- Effects outside established metabolic endpoints  

Ongoing trials and real-world observational data are expected to further clarify these questions.

---

## References

### Core randomized controlled trials
- Wilding JPH et al. *Once-Weekly Semaglutide in Adults with Overweight or Obesity.*  
  **New England Journal of Medicine**, 2021.  
  PMID: **33567185**  
  (STEP 1 trial â€“ obesity)

- Davies M et al. *Semaglutide 2.4 mg once a week in adults with overweight or obesity.*  
  **Nature Medicine**, 2021.  
  PMID: **33664455**  
  (STEP program overview)

- Marso SP et al. *Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.*  
  **New England Journal of Medicine**, 2016.  
  PMID: **27633186**  
  (SUSTAIN-6 â€“ cardiovascular outcomes)

- AhrÃ©n B et al. *Efficacy and safety of once-weekly semaglutide versus exenatide ER.*  
  **The Lancet Diabetes & Endocrinology**, 2017.  
  PMID: **28602705**  
  (SUSTAIN-3 â€“ comparator trial)

---

### Pharmacology & mechanism reviews
- Nauck MA, Meier JJ. *Incretin hormones: Their role in health and disease.*  
  **Diabetes, Obesity and Metabolism**, 2018.  
  PMID: **29364563**

- Drucker DJ. *Mechanisms of Action and Therapeutic Application of GLP-1.*  
  **Cell Metabolism**, 2018.  
  PMID: **29397273**

---

### Safety & tolerability
- Kushner RF et al. *Gastrointestinal tolerability of once-weekly semaglutide.*  
  **Diabetes, Obesity and Metabolism**, 2020.  
  PMID: **31833144**

- Holst AG et al. *Safety of semaglutide.*  
  **Expert Opinion on Drug Safety**, 2018.  
  PMID: **30084258**

